Clinical Trial Update: Safety & Immunogenicity of Pneumococcal Vaccine 2189242A Co-administered With DTPa-HBV-IPV/Hib in Healthy Infants [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating safety and immunogenicity of a pneumococcal vaccine co-administered with DTPa-HBV-IPV/Hib in healthy infants; results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Infections Streptococcal
• Streptococcal Infections

Drugs mentioned

• DTPa-HBV-IPV/Hib (Diphtheria and tetanus toxoids and acellular pertussis vaccine; Hepatitis B vaccine; Inactivated poliovirus vaccine; Haemophilus influenzae type b conjugate vaccine)
• Pneumococcal Vaccine 2189242A

Snippet

Sponsor: GlaxoSmithKline | Conditions: Infections, Streptococcal | Phase 2 | Status: COMPLETED | Results posted: 2016-09-28